Vitestro Secures $70 Million to Propel Autonomous Blood Collection Robotics Forward Vitestro has successfully raised $70 million in oversubscribed Series B funding to enhance its autonomous blood collection technology and ensure regulatory readiness.

Vitestro Secures $70 Million to Propel Autonomous Blood Collection Robotics Forward #Netherlands #Utrecht #blood_collection #Vitestro #Aletta

Growing Blood Collection Devices Market Projected to Reach $13.02 Billion by 2030 The global Blood Collection Devices Market is anticipated to grow from $8.61 billion in 2024 to $13.02 billion by 2030, driven by rising chronic diseases and innovative diagnostics.

Growing Blood Collection Devices Market Projected to Reach $13.02 Billion by 2030 #None #blood_collection #Healthcare_Market #Diagnostic_Devices

YourBio Health Launches Scientific Advisory Board to Revolutionize Blood Collection YourBio Health introduces its Scientific Medical Advisory Board, uniting experts to innovate painless blood collection for better diagnostics globally.

YourBio Health Launches Scientific Advisory Board to Revolutionize Blood Collection #USA #Boston #blood_collection #YourBio_Health #TAP

YourBio Health Expands Leadership Team for Future Success in Blood Collection Technology YourBio Health has strengthened its leadership with key appointments aiming to enhance the growth of remote blood collection technology, making healthcare more accessible.

YourBio Health Expands Leadership Team for Future Success in Blood Collection Technology #USA #blood_collection #Medford #YourBio_Health #TAP_Device

Haemonetics Finalizes Strategic Sale of Whole Blood Assets to GVS, S.p.A Haemonetics Corporation has finalized the sale of its whole blood assets to GVS, S.p.A for a total of up to $67.8 million. This transaction aims to focus on growth initiatives in medical technology.

Haemonetics Finalizes Strategic Sale of Whole Blood Assets to GVS, S.p.A #United_States #Boston #Haemonetics #GVS #blood_collection

Haemonetics Completes Deal to Sell Whole Blood Assets to GVS for Up to $67.1 Million Haemonetics has announced the sale of its whole blood assets to GVS, S.p.A for $67.1 million, streamlining its focus on medical solutions and patient care.

Haemonetics Completes Deal to Sell Whole Blood Assets to GVS for Up to $67.1 Million #United_States #Boston #Haemonetics #GVS #blood_collection